As a major attractant of BM-derived cells that contribute to the creation of a tumor-supportive TME, the CCL2/CCR2 axis is of clinical relevance (discussed under ‘Modulating the immune TME’) (15). This evidence concerns the gene CCL2 and neoplasm.